Is Gilead Sciences financially healthy?

On 30 September 2026 Gilead Sciences held 6.44B USD in cash and short-term investments against total debt of 26.23B USD. Its current ratio is 1.38: what falls due within a year against what turns into cash within a year. Over the last twelve months it generated 13.78B USD of free cash flow.

Is Gilead Sciences growing?

Gilead Sciences's revenue grew 3.6% a year over its last five fiscal years, from 24.69B USD in fiscal year 2020 to 29.44B USD in fiscal year 2025. Over the last twelve months it was up 6.5% on the twelve months before.

Where can I find Gilead Sciences's annual report (10-K)?

Gilead Sciences files its annual report (Form 10-K) and its quarterly reports (Form 10-Q) with the US Securities and Exchange Commission, on its EDGAR site; the figures on these pages come from them.

Gilead Sciences
D
Quotes are delayed by 15 minutes

GILD

Arincen ScoreBeta87/100

87/100B

166.870

USD

-0.73

(-0.44%)

Pre Open·168.040USD+1.170(+0.70%)

Last updated: 9 Nov, 07:01 GMT-5 · Delayed 15 min

Q4 FY2026 · Earnings report

EPS estimate 1.39Revenue estimate 8.28B

Q4 FY2026 · Earnings report

Tuesday 9 February

EPS estimate 1.39Revenue estimate 8.28B

Q4 FY2026 · Earnings report

EPS estimate 1.39Revenue estimate 8.28B

Q4 FY2026 · Earnings report

Tuesday 9 February

EPS estimate 1.39Revenue estimate 8.28B

Overview Financials Forecast Earnings Dividends Company

Gilead Sciences financials

Not at the moment. Gilead Sciences lost 3.86B USD over the last twelve months. It made a profit in 23 of its 35 fiscal years since 1990. Its last loss was in fiscal year 2006.

Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.: 30.99B USD
Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.: -3.86B USD
Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.: 13.78B USD
Cash and short-term investments: 6.44B USD
Total debt: 26.23B USD
Shareholders' equityWhat is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.: 13.04B USD

Cash, debt and equity as of 30 Sept 2026.

Gilead Sciences earnings

Next earnings · Q4 FY2026

9 Feb 2027

EPS estimate

1.39 USD

Revenue estimate

8.28B USD

Last quarter · Q3 FY2026

EPS2.55Beat +16.4%Revenue8.30BBeat +6.3%

Revenue

ReportedEstimate

EPS

ReportedEstimate

Period	Report date	EPS estimate	Reported EPS	Surprise	EPS growth	Revenue estimate	Reported revenue	Surprise	Revenue growth
Q1 FY2027	—	2.17	—	—	+7.12%	7.49B	—	—	+7.60%
Q4 FY2026	9 Feb 2027	1.39	—	—	-25.27%	8.28B	—	—	+4.52%
Q3 FY2026	29 Oct 2026	2.19	2.55	+16.44%	+3.24%	7.81B	8.30B	+6.34%	+6.83%
Q2 FY2026	4 Aug 2026	-7.25	-6.75	+6.90%	-435.82%	7.40B	7.80B	+5.47%	+10.20%
Q1 FY2026	7 May 2026	1.91	2.03	+6.28%	+12.15%	6.91B	6.96B	+0.67%	+4.39%
Q4 FY2025	10 Feb 2026	1.81	1.86	+2.76%	-2.11%	7.69B	7.93B	+3.05%	+4.70%
Q3 FY2025	30 Oct 2025	2.13	2.47	+15.96%	+22.28%	7.45B	7.77B	+4.35%	+2.97%
Q2 FY2025	7 Aug 2025	1.96	2.01	+2.55%	0.00%	6.98B	7.08B	+1.43%	+1.90%

Period	EPS estimate	Reported EPS	Surprise	EPS growth	Revenue estimate	Reported revenue	Surprise	Revenue growth
FY2028	10.78	—	—	+6.70%	34.78B	—	—	+3.84%
FY2027	10.10	—	—	—	33.49B	—	—	+7.10%
FY2026	-0.85	—	—	-110.41%	31.27B	—	—	+6.20%
FY2025	8.11	8.15	+0.46%	+76.79%	29.23B	29.44B	+0.73%	+2.41%
FY2024	4.41	4.61	+4.54%	-31.40%	28.32B	28.75B	+1.51%	+6.02%
FY2023	6.75	6.72	-0.51%	-7.57%	27.10B	27.12B	+0.06%	-0.60%
FY2022	7.10	7.27	+2.35%	-0.27%	26.53B	27.28B	+2.84%	-0.09%

Gilead Sciences growth and profitability

Full income statement

Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.: 30.99B USD
Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.: -3.86B USD
Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.: 79.93%
Operating margin: -7.62%
Net margin: -12.47%

Revenue / Net income

Revenue Net income Net margin

Period	Revenue	Growth	Net income	Growth	Gross margin	Operating margin	Net margin	EBITDA	Growth
FY2025	29.44B	+2.39%	8.51B	+1,672.92%	78.83%	34.04%	28.90%	13.58B	+206.27%
FY2024	28.75B	+6.04%	480.00M	-91.53%	78.26%	5.78%	1.67%	4.43B	-57.76%
FY2023	27.12B	-0.60%	5.67B	+23.37%	76.04%	28.05%	20.89%	10.50B	+18.57%
FY2022	27.28B	-0.09%	4.59B	-26.23%	79.26%	26.87%	16.83%	8.85B	-21.86%
FY2021	27.31B	+10.60%	6.23B	+4,960.98%	75.82%	36.32%	22.80%	11.33B	+174.11%

Period	Revenue	Net income	Gross margin	Operating margin	Net margin
Q3 FY2026	8.30B	2.43B	81.07%	41.71%	29.27%
Q2 FY2026	7.80B	-10.50B	79.76%	-133.21%	-134.51%
Q1 FY2026	6.96B	2.02B	79.24%	37.16%	29.04%
Q4 FY2025	7.92B	2.18B	79.51%	25.04%	27.55%
Q3 FY2025	7.77B	3.05B	79.80%	42.82%	39.28%

How Gilead Sciences makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.

Biktarvy14.33B 48.7%

Descovy2.76B 9.4%

Genvoya1.50B 5.1%

Yescarta1.50B 5.1%

Trodelvy1.40B 4.7%

Sofosbuvir/Velpatasvir1.27B 4.3%

Odefsey1.17B 4.0%

Vemlidy1.07B 3.6%

Veklury911.00M 3.1%

Other Liver Disease874.00M 3.0%

Royalty, contract and other revenues527.00M 1.8%

AmBisome509.00M 1.7%

Other HIV500.00M 1.7%

Symtuza - Revenue share495.00M 1.7%

Tecartus344.00M 1.2%

Other290.00M 1.0%

Revenue29.44B 100.0%

Cost of revenue6.23B 21.2%

Gross profit23.21B 78.8%

Research and development5.80B 19.7%

Selling and administration5.71B 19.4%

Other operating expenses1.68B 5.7%

Operating income10.02B 34.0%

Tax1.29B 4.4%

Other expense226.00M 0.8%

Net income8.51B 28.9%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Gilead Sciences revenue breakdown

By product

FY2025

48.7%Biktarvy9.4%Descovy5.1%Genvoya5.1%Yescarta4.7%Trodelvy4.3%Sofosbuvir/Velpatasvir4.0%Odefsey3.6%Vemlidy3.1%Veklury3.0%Other Liver Disease1.8%Royalty, contract and other revenues1.7%AmBisome1.7%Other HIV1.7%Symtuza - Revenue share1.2%Tecartus

Segment	Revenue	Share of revenue	Change on the year
Biktarvy	14.33B	48.7%	—
Descovy	2.76B	9.4%	—
Genvoya	1.50B	5.1%	—
Yescarta	1.50B	5.1%	—
Trodelvy	1.40B	4.7%	+6.2%
Sofosbuvir/Velpatasvir	1.27B	4.3%	—
Odefsey	1.17B	4.0%	—
Vemlidy	1.07B	3.6%	—
Veklury	911.00M	3.1%	-49.4%
Other Liver Disease	874.00M	3.0%	—
Royalty, contract and other revenues	527.00M	1.8%	—
AmBisome	509.00M	1.7%	—
Other HIV	500.00M	1.7%	-97.5%
Symtuza - Revenue share	495.00M	1.7%	—
Tecartus	344.00M	1.2%	—
Other	290.00M	1.0%	—

By region

FY2025

70.9%United States17.2%Europe11.9%Other International

Region	Revenue	Share of revenue	Change on the year
United States	20.88B	70.9%	+1.4%
Europe	5.06B	17.2%	+9.3%
Other International	3.50B	11.9%	-0.7%

Operating and free cash flow

Full cash flow statement

Operating cash flow Free cash flow

Fiscal year	Operating cash flow	Free cash flow
FY2025	10.02B	9.46B
FY2024	10.83B	10.31B
FY2023	8.01B	7.42B
FY2022	9.07B	8.34B
FY2021	11.38B	10.81B
FY2020	8.17B	7.52B
FY2019	9.14B	8.32B
FY2018	8.40B	7.48B
FY2017	11.90B	11.31B
FY2016	17.05B	16.30B

Gilead Sciences financial health

Full balance sheet

Cash and short-term investments: 6.44B USD
Total debt: 26.23B USD
Net cash: -19.79B USD
Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.: 13.78B USD
Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.: 1.38
Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.: 2.01
Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.: 5 / 9
Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.: 3.90

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow

Fiscal year	Cash and short-term investments	Total debt	Free cash flow
FY2025	9.61B	24.94B	9.46B
FY2024	11.57B	26.71B	10.31B
FY2023	7.26B	24.99B	7.42B
FY2022	6.39B	25.23B	8.34B
FY2021	6.52B	26.70B	10.81B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity

Fiscal year	Total assets	Total liabilities	Shareholders' equity
FY2025	59.02B	36.41B	22.70B
FY2024	59.00B	39.75B	19.33B
FY2023	62.13B	39.38B	22.83B
FY2022	63.17B	41.96B	21.24B
FY2021	67.95B	46.89B	21.07B
FY2020	68.41B	50.19B	18.20B
FY2019	61.63B	38.98B	22.53B
FY2018	63.68B	42.14B	21.39B
FY2017	70.28B	49.78B	20.44B
FY2016	56.98B	37.61B	18.89B

Gilead Sciences valuation

Forward P/E (FY2027)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.: 16.52
Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.: 6.68
Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.: 15.87
EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.: 275.54

Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.

Market capitalization

206.98B USD

Total debt

26.23B USD

−

Cash and short-term investments

6.44B USD

Enterprise value

226.77B USD

Valuation over time

P/EForward P/EForward P/E · Estimate

Fiscal year	P/E	Forward P/E	P/S	P/B	EV/EBITDA
FY2028 (est.)	15.48	—	—	—	—
FY2027 (est.)	16.52	15.48	—	—	—
Now (TTM)	—	19.53	6.68	15.87	275.54
FY2025	17.94	11,566.18	5.19	6.73	12.52
FY2024	243.08	11.38	4.01	5.96	29.75
FY2023	17.84	18.32	3.73	4.43	11.43
FY2022	23.46	12.71	3.95	5.07	14.41
FY2021	14.64	10.22	3.34	4.33	9.94

Gilead Sciences against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Amgen, Pfizer, Bristol-Myers Squibb, Merck & Co., AbbVie, and Johnson & Johnson, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

Gross marginAbove its median78.8%
75.8%79.3%
Against its peers: 1 of 7Peers' median 70.9%
Operating marginAbove its median34.0%
5.8%36.3%
Against its peers: 2 of 7Peers' median 28.8%
Net marginHighest in 5 years28.9%
1.7%28.9%
Against its peers: 1 of 7Peers' median 17.8%
Return on equityHighest in 5 years37.5%
2.5%37.5%
Against its peers: 3 of 6Peers' median 34.7%
Free cash flow marginAt its median32.1%
27.4%39.6%
Against its peers: 1 of 7Peers' median 21.5%
Revenue growthAt its median2.4%
-0.6%10.6%
Against its peers: 4 of 7Peers' median 3.6%
EPS growthAbove its median1,684.2%
-91.6%4,961.6%
Against its peers: 1 of 6Peers' median 8.0%
Debt to EBITDALowest in 5 years1.84×
1.84×6.02×
Against its peers: 3 of 7Peers' median 3.16×
Current ratioAbove its median1.55
1.271.60
Against its peers: 1 of 7Peers' median 1.15

Figure	FY2025	5-year low – high	Against its history	Against its peers
Gross margin	78.8%	75.8%79.3%	Above its median	1 of 7
Operating margin	34.0%	5.8%36.3%	Above its median	2 of 7
Net margin	28.9%	1.7%28.9%	Highest in 5 years	1 of 7
Return on equity	37.5%	2.5%37.5%	Highest in 5 years	3 of 6
Free cash flow margin	32.1%	27.4%39.6%	At its median	1 of 7
Revenue growth	2.4%	-0.6%10.6%	At its median	4 of 7
EPS growth	1,684.2%	-91.6%4,961.6%	Above its median	1 of 6
Debt to EBITDA	1.84×	1.84×6.02×	Lowest in 5 years	3 of 7
Current ratio	1.55	1.271.60	Above its median	1 of 7

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Gilead Sciences dividends

Annual dividend: 3.28 USD
Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.: 1.97%
Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.: 11
Frequency: Quarterly
Next payment: 0.82 USD
Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.: 15 Dec 2026
Next payment date: 30 Dec 2026

Dividends per share

Year	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Dividends per share	3.16	3.08	3.00	2.92	2.84	2.72	2.52	2.28	2.08	1.84

Gilead Sciences ownership

InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.: 90.19%
Institutional holders: 2,377 (-37)
Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.: 99.79%

Who owns the shares

Institutions 90.2% Others 9.8%

As of 30 Jun 2026

Shares free to trade

Free float 1.24B shares ·99.8% Closely held 2.63M shares ·0.2%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

Quarter	Sales	Shares acquired	Shares disposed of
Q4 2026	12	128.31K	292.62K
Q3 2026	26	71.72K	193.87K
Q2 2026	16	88.73K	116.16K
Q1 2026	17	923.23K	772.18K

Shares outstanding

Basic shares Diluted shares Change in diluted shares

Fiscal year	Basic shares	Diluted shares	Change in diluted shares
FY2025	1.24B	1.26B	0.00%
FY2024	1.25B	1.26B	-0.24%
FY2023	1.25B	1.26B	-0.32%
FY2022	1.26B	1.26B	0.00%
FY2021	1.26B	1.26B	-0.08%

Common questions about Gilead Sciences's financials

Source: Financial Modeling Prep

Gilead Sciences
D
Quotes are delayed by 15 minutes

GILD

Gilead Sciences financials

Gilead Sciences earnings

Revenue

EPS

Gilead Sciences growth and profitability

Revenue / Net income

How Gilead Sciences makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.

Gilead Sciences revenue breakdown

By product

By region

Operating and free cash flow

Gilead Sciences financial health

Cash, debt and free cash flow

Assets, liabilities and equity

Gilead Sciences valuation

Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.

Valuation over time

Gilead Sciences against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.

Gilead Sciences dividends

Dividends per share

Gilead Sciences ownership

Who owns the shares

Shares free to trade

Insider trading

Shares outstanding

Common questions about Gilead Sciences's financials

Is Gilead Sciences profitable?

Is Gilead Sciences financially healthy?

Is Gilead Sciences growing?

Where can I find Gilead Sciences's annual report (10-K)?

Need help?

Gilead Sciences DQuotes are delayed by 15 minutes

GILD

Gilead Sciences financials

Gilead Sciences earnings

Revenue

EPS

Gilead Sciences growth and profitability

Revenue / Net income

How Gilead Sciences makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.

Gilead Sciences revenue breakdown

By product

By region

Operating and free cash flow

Gilead Sciences financial health

Cash, debt and free cash flow

Assets, liabilities and equity

Gilead Sciences valuation

Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.

Valuation over time

Gilead Sciences against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.

Gilead Sciences dividends

Dividends per share

Gilead Sciences ownership

Who owns the shares

Shares free to trade

Insider trading

Shares outstanding

Common questions about Gilead Sciences's financials

Is Gilead Sciences profitable?

Is Gilead Sciences financially healthy?

Is Gilead Sciences growing?

Where can I find Gilead Sciences's annual report (10-K)?

Need help?

Gilead Sciences
D
Quotes are delayed by 15 minutes